Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes

NCT03132181 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Diabetes Mellitus Type 2 (T2DM)

Interventions

DRUG: Empagliflozin
OTHER: Placebo

Sponsor

RWTH Aachen University

Collaborators

[object Object]